Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(20 sites)

France

CHU Amiens Picardie_Site Sud, Amiens

Institut Sainte Catherine, Avignon

Centre Hospitalier de la Côte Basque, Bayonne

CHU Jean Minoz, Besançon

Polyclinique Bordeaux Nord Aquitaine, Bordeaux

Centre François Baclesse, Caen

Centre Georges-François Leclerc, Dijon

CHD Vendee, La Roche-sur-Yon

Centre Oscar Lambret, Lille

Centre Léon Bérard, Lyon

Institut Paoli-Calmettes, Marseille

Institut Curie, Paris

Clinique de La Croix du sud, Quint-Fonsegrives

Institut Godinot, Reims

Institut Curie, Saint-Cloud

Clinique Mutualiste de l'Estuaire, Saint-Nazaire

Centre Paul Strauss, Strasbourg

Institut Claudius Regaud, IUCT Oncopole, Toulouse

CHU Bretonneau, Tours

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy